{
    "organizations": [],
    "uuid": "17637b4db43d3020002c08ca724178f5a8ff8aba",
    "author": "",
    "url": "https://www.reuters.com/article/brief-roivant-sciences-and-arqule-enter/brief-roivant-sciences-and-arqule-enter-into-license-agreement-for-derazantinib-in-china-idUSFWN1PX111",
    "ord_in_thread": 0,
    "title": "BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 7, 2018 / 12:07 PM / in 11 minutes BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China Reuters Staff \nFeb 7 (Reuters) - Arqule Inc: \n* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA \n* ARQULE INC - ‍DEAL TERMS INCLUDE AN UPFRONT PAYMENT TO ARQULE OF $3 MILLION AND AN ADDITIONAL $2.5 MILLION DEVELOPMENT MILESTONE WITHIN FIRST YEAR​ \n* ARQULE INC - ARQULE IS ALSO ELIGIBLE FOR REGULATORY AND COMMERCIAL MILESTONES AND ROYALTIES ON FUTURE SALES OF DERAZANTINIB IN GREATER CHINA \n* ARQULE INC - COLLABORATION BETWEEN CO AND ROIVANT WILL EXPAND CLINICAL DEVELOPMENT OF DERAZANTINIB \n* ARQULE - ‍ GRANTED A ROIVANT UNIT AN EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE DERAZANTINIB IN PEOPLE‘S REPUBLIC OF CHINA, HONG KONG, MACAU, TAIWAN​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-07T14:07:00.000+02:00",
    "crawled": "2018-02-07T14:21:26.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "science",
        "arqule",
        "enter",
        "license",
        "agreement",
        "derazantinib",
        "china",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "arqule",
        "inc",
        "roivant",
        "science",
        "arqule",
        "enter",
        "license",
        "agreement",
        "derazantinib",
        "china",
        "arqule",
        "inc",
        "term",
        "include",
        "upfront",
        "payment",
        "arqule",
        "million",
        "additional",
        "million",
        "development",
        "milestone",
        "within",
        "first",
        "arqule",
        "inc",
        "arqule",
        "also",
        "eligible",
        "regulatory",
        "commercial",
        "milestone",
        "royalty",
        "future",
        "sale",
        "derazantinib",
        "greater",
        "china",
        "arqule",
        "inc",
        "collaboration",
        "co",
        "roivant",
        "expand",
        "clinical",
        "development",
        "derazantinib",
        "arqule",
        "granted",
        "roivant",
        "unit",
        "exclusive",
        "license",
        "develop",
        "commercialize",
        "derazantinib",
        "people",
        "republic",
        "china",
        "hong",
        "kong",
        "macau",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}